Novavax (NVAX) shares soared 19.2% in the last trading session to close at $14.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.8% loss over the past four weeks. Last month, the FDA granted emergency use authorization to an updated version of the company's proteinbased COVID-19 vaccine for individuals aged 12 years and older. The vaccine has been designed to target the JN.1 strain. Following this nod, Novavax's updated vacci ...

Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organization Dr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platform GAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvan ...

The latest trading session saw Novavax (NVAX) ending at $12.80, denoting a -0.85% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.28%. Meanwhile, the Dow experienced a rise of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.15%. Coming into today, shares of the vaccine maker had gained 7.67% in the past month. In that same time, the Medical sector gained 0.38%, while the S&P 500 gained 2%. The upcoming earnings release of Novavax will b ...

COVID-19 Positive Rate Spikes With more knowledge about the virus, ample funding, and new treatments, the worst of the COVID-19 pandemic seems to be behind us (from a death perspective). However, just because the Coronavirus death rate has dropped dramatically since its major peak in 2020 (and a subsequent spike in 2021) doesn't mean that COVID-19 is still not negatively impacting people who get it. Data from the CDC website shows that the number of people testing positive for COVID-19 has reached its highe ...

Doses of Novavax's 2024-2025 Formula COVID-19 vaccine now available at thousands of locations nationwide Novavax's updated vaccine is the only protein-based option available in the U.S. this fall for individuals aged 12 and older GAITHERSBURG, Md., Sept. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-1 ...

The biotech continues to earn important wins, but is it enough? Vaccine maker Novavax (NVAX -3.01%) is having a good year. In May, the company announced a lucrative partnership with French biotech giant Sanofi (SNY -1.24%), sending its stock price soaring. Novavax has made quite a comeback for a company that raised doubts about its ability to stay in business just 18 months ago. But Novavax isn't done. The biotech just announced a regulatory win that has some investors excited. Let's find out whether Novava ...

Novavax, Inc. (NASDAQ:NVAX) Baird 2024 Global Healthcare Conference September 10, 2024 3:10 PM ET Unidentified Company Representative I'd like to thank you all for joining us for Novavax Corporate presentation certainly for Baird for having us here again this year. This is always such a great forum and it coincides with the beginning of the vaccination season for COVID vaccines. We're going to talk a lot about our technology today, but really important announcement just very recently with the authorization ...

Novavax, Inc. (NASDAQ:NVAX) Baird 2024 Global Healthcare Conference September 10, 2024 3:10 PM ET Unidentified Company Representative I'd like to thank you all for joining us for Novavax Corporate presentation certainly for Baird for having us here again this year. This is always such a great forum and it coincides with the beginning of the vaccination season for COVID vaccines. We're going to talk a lot about our technology today, but really important announcement just very recently with the authorization ...

Novavax, Inc. (NASDAQ:NVAX) H.C. Wainwright 26th Annual Global Investment Conference September 9, 2024 3:30 PM ET Company Participants Jim Kelly - CFO Bob Walker - Head of R&D Conference Call Participants Vernon Bernardino - H.C. Wainwright Vernon Bernardino Okay. Good afternoon, everybody. Welcome to the 26th Annual H.C. Wainwright Global Investment Conference. Our next company presenting are -- that we're having a chat today is Novavax, company that by now, hopefully, all of you know really well. They hav ...

Regulators recently approved an updated COVID shot from Novavax. Struggling biotech Novavax (NVAX -0.72%) was a hot buy a few years ago as it was in the midst of developing a vaccine for COVID-19. Ultimately, it did produce an approved vaccine, but it was a bit late and did not end up generating nearly as much in revenue as it could have if it had obtained approval much earlier. And since 2022, a sell-off has ensued, with the stock losing more than 91% of its value. Recently, there's been some renewed excit ...